• News release
  • /
  • In brief
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
XuanZhu Pharma Co., Ltd. is an international research and development (R&D) enterprise of innovative drugs. Founded in 2002 with the registered capital of 50 million yuan,XuanZhu Pharma is focused on R&D of new chemical entities. It is a wholly-owned subsidiary and innovative drug research institute of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharma). Sihuan Pharma, listed in Hong Kong (stock code: 00460.HK) on October 28, 2010, has developed into a multi-functional pharmaceutical group company, covering ...
Picture Display
  • Our products
  • /
  • Research Overview
XuanZhu Pharma’s R&D efforts are now focused on multiple therapeutic areas, such as antibiotics, cardiovascular disease, oncology and diabetes, with more than 10 molecular targets each year.

Email | Terms of Use | Sihuan Pharma | Contact us | Sihuan Pharma Networking Academy
Copyright © 2014 Sihuan Pharmaceutical Holdings Group Ltd. All rights reserved 鲁ICP备09030169号

轩竹微信公众号